2018
Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1311-1317. PMID: 30033575, PMCID: PMC6220789, DOI: 10.1002/ajh.25228.Peer-Reviewed Original ResearchConceptsIndolent non-Hodgkin lymphomaDose-limiting toxicityNon-Hodgkin lymphomaClinical activityINHL patientsHematologic malignanciesClinical developmentGrade 3 transaminase elevationMedian progression-free survivalOral dual inhibitorAcute respiratory failureE. coli sepsisElevated liver enzymesOpen-label studyAcceptable safety profileAdvanced hematologic malignanciesDose-escalation phaseGrade 3 rashProgression-free survivalSevere adverse eventsPhase 1 studyDuration of responseFavorable clinical activityFurther clinical developmentBID cohortA Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2017
Neurolymphomatosis of the thoracic sympathetic chain
Kaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM. Neurolymphomatosis of the thoracic sympathetic chain. Neurology 2017, 89: 1926-1927. PMID: 28939669, PMCID: PMC5664295, DOI: 10.1212/wnl.0000000000004600.Peer-Reviewed Original Research
2013
Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphoma
Chen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Wang C, Dai M, Liu Z, Ma S, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphoma. American Journal Of Hematology 2013, 88: 606-611. PMID: 23619945, PMCID: PMC3902049, DOI: 10.1002/ajh.23463.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBody Mass IndexCase-Control StudiesDNA RepairDNA-Binding ProteinsExodeoxyribonucleasesFemaleGenotypeHumansLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMiddle AgedPolymorphism, GeneticRecQ HelicasesRisk FactorsUbiquitin-Protein LigasesWerner Syndrome HelicaseX-ray Repair Cross Complementing Protein 1Xeroderma Pigmentosum Group D ProteinConceptsBody mass indexNon-Hodgkin lymphomaDNA repair pathway genesCT/TTMass indexNHL riskPopulation-based case-control studyRisk of NHLDiffuse large B-cell lymphomaGT/TT genotypesLarge B-cell lymphomaAC/CCT-cell lymphomaCase-control studyB-cell lymphomaConnecticut womenTT genotypeGG genotypePathway genesLymphomaCommon genetic variationWomenRiskSignificant interaction
2012
Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma
Kim C, Zheng T, Lan Q, Chen Y, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 866-868. PMID: 22374993, PMCID: PMC3394153, DOI: 10.1158/1055-9965.epi-12-0010.Peer-Reviewed Original ResearchConceptsRisk of NHLBody mass indexNon-Hodgkin lymphomaOxidative stress pathway genesStress pathway genesStudies of BMIPopulation-based case-control studyOxidative stressPathway single nucleotide polymorphismsOverweight/obeseCase-control studyLarger study populationIncreases oxidative stressFalse discovery rate adjustmentHistologic subtypeMass indexRisk factorsConnecticut womenNHL riskStudy populationUnderweight individualsCommon genetic variationOxidative stress genesGenetic polymorphismsSingle nucleotide polymorphisms
2011
Polymorphisms in immune function genes and non-Hodgkin lymphoma survival
Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2011, 6: 102-114. PMID: 22113576, PMCID: PMC3326600, DOI: 10.1007/s11764-010-0164-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCase-Control StudiesConnecticutCytokinesDisease-Free SurvivalFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateLymphoma, Non-HodgkinMiddle AgedModels, GeneticPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSocioeconomic FactorsSurvival AnalysisSurvivorsYoung AdultConceptsNon-Hodgkin lymphomaNHL survivalHazard ratioCytokine genesNon-Hodgkin lymphoma survivalCox proportional hazards modelIncident NHL casesConnecticut Tumor RegistryDisease-free survivalKaplan-Meier curvesRisk of deathProportional hazards modelCombination of polymorphismsImmune function genesIL6 genotypeNHL prognosisTumor RegistryHistologic typeTumor characteristicsDecreased riskSecondary cancersNHL casesTumor interactionCancer occurrenceLymphoma survival
2010
Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma
Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, Dai M, Li Y, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2010, 117: 585-590. PMID: 20952689, PMCID: PMC3031482, DOI: 10.1182/blood-2010-07-295097.Peer-Reviewed Original ResearchConceptsBody mass indexNon-Hodgkin lymphomaAG/GGB-cell lymphomaMass indexCommon B-cell lymphoma subtypesSmall lymphocytic lymphoma/chronic lymphocytic leukemiaRisk of NHLMarginal zone B-cell lymphomaCT/TT genotypesB-cell lymphoma subtypesT-cell lymphomaCase-control studyCT/TTChronic lymphocytic leukemiaNHL overallConnecticut womenNHL riskLymphocytic leukemiaLymphoma subtypesTh2 cytokine genesFollicular lymphomaTT genotypeSignificant interactionLymphomaVegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women
Han X, Zheng T, Foss F, Holford TR, Shuangge M, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leukemia & Lymphoma 2010, 51: 1047-1054. PMID: 20350273, PMCID: PMC3110752, DOI: 10.3109/10428191003690364.Peer-Reviewed Original ResearchConceptsHazard ratioHigh intakeNon-Hodgkin lymphoma survivalCox proportional hazards modelRisk of deathIntake of vegetablesProportional hazards modelCitrus fruit consumptionIncident NHLOverall survivalNHL patientsGreen leafy vegetablesFruit intakeNHL subtypesFemale casesConnecticut womenNHL survivalLymphoma survivalHazards modelFruit consumptionIntakeSurvivalPatientsNHLUseful strategy
2009
Alcohol consumption and non-Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2009, 4: 101-109. PMID: 20039144, PMCID: PMC3141078, DOI: 10.1007/s11764-009-0111-4.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaNon-Hodgkin lymphomaAlcohol consumptionHazard ratioNHL subtypesNHL survivalNon-Hodgkin lymphoma survivalCox proportional hazards modelLarge B-cell lymphomaDisease-free survivalBetter overall survivalKaplan-Meier methodModerate alcohol drinkersProportional hazards modelB-cell lymphomaLower death ratesIntroductionEpidemiological studiesFree survivalOverall survivalNHL patientsAlcohol drinkersIncident casesMethodsA cohortAlcohol drinkingDLBCL patients